PURPOSE: The purpose of this study is to evaluate the safety and efficacy of pimagedine, as compared to placebo, in patients with type II diabetes and overt diabetic nephropathy. Chronic hyperglycemia in patients with type II diabetes can lead to a variety of complications including nephropathy and retinopathy. One of the major pathophysiological mechanisms by which hyperglycemia may lead to characteristic irreversible tissue damage is the formation of glucose-derived cross links in proteins (advanced glycated endproducts [AGE's]) that result in increased stiffness, abnormal protein accumulation, membrane leakiness and dysfunction. Patients with diabetes have been shown to have higher levels of serum AGE's than non-diabetic subjects, and the AGE levels are proportional to the severity of diabetic nephropathy. Also, reactive intermediates formed during periods of hyperglycemia may continue to cross-link with proteins even after blood glucose is lowered. Therefore, normalization of blood glucose may not completely prevent the progression of complications. METHODS: This is a phase III, double-blind, randomized, placebo-controlled study which will evaluate 900 patients at 70 sites in North America. Patients will be randomized to either a placebo or one of two dose levels of pimagedine. However, the dosage of pimagedine may be changed during the course of the study, based on creatinine clearance rates. Each patient is evaluated at several month intervals for blood pressure, Hemoglobin A1c, kidney function, and general chemistry and hematology profiles. Patients have a Glomerular Filtration Rate test at 3 month intervals and a dilated eye examination yearly.

Project Start
Project End
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247
Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417
Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213
Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17
Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79
Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32

Showing the most recent 10 out of 128 publications